Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis
Portal vein thrombosis (PVT) is associated with a higher risk of liver-related complications. Recent guidelines recommend direct-acting anticoagulants (DOAC) in patients with cirrhosis and non-tumoral PVT. However, data on the efficacy and safety of DOAC in these patients remain limited. We aim to investigate the efficacy and safety of DOAC compared to vitamin K antagonists (VKA) to treat non-tumoral PVT in patients with cirrhosis.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Jin Hean Koh, Zi Hui Liew, Gin Kee Ng, Hui Ting Liu, Yew Chong Tam, Andrea De Gottardi, Yu Jun Wong Tags: Meta-Analysis Source Type: research
More News: Cirrhosis | Gastroenterology | Liver | Liver Disease | Thrombosis | Urology & Nephrology | Vitamin K | Vitamins